Brief: Transgene And Bioinvent Receive CTA Approval For Phase 1/2A Trial Of Oncolytic Virus BT-001 In Solid Tumors

BioInvent International AB

21/12/2020 07:34

Dec 21 (Reuters) - Transgene  TRNG.PA :
    * TRANSGENE AND BIOINVENT RECEIVE CTA APPROVAL FOR PHASE
1/2A
TRIAL OF ONCOLYTIC VIRUS BT-001 IN SOLID TUMORS

Source text for Eikon:  ID:nBw4JyDTBa 
Further company coverage:  BINV.ST ,  TRNG.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))